Adempas (riociguat) Patient Assistance Program
Don’t let the high cost of brand soluble guanylate cyclase stimulator disrupt your pulmonary hypertension treatment. We help eligible patients access Adempas (riociguat tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Adempas (riociguat) is FDA-approved for pulmonary arterial hypertension (PAH — WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH — WHO Group 4) — currently the only FDA-approved oral therapy for CTEPH. Soluble guanylate cyclase (sGC) stimulator — first-in-class mechanism distinct from PDE5 inhibitors.
- Without assistance, Adempas costs commonly run approximately $16,000–$20,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Adempas for a flat $69.95 per month.
- Other PAH therapies: PDE5 inhibitors (sildenafil/Revatio — generic; tadalafil/Adcirca — generic), endothelin receptor antagonists (ambrisentan, bosentan — generic; macitentan/Opsumit), prostacyclin pathway (epoprostenol, treprostinil, iloprost, selexipag/Uptravi), sotatercept (Winrevair). For CTEPH: pulmonary endarterectomy (potentially curative); balloon pulmonary angioplasty; Adempas is the only FDA-approved oral drug for CTEPH. Adempas is contraindicated with PDE5 inhibitors and nitrates — severe hypotension risk.
What is Adempas Prescription Assistance Program?
The Adempas Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Adempas (used for PAH and CTEPH) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but enrollment involves detailed applications, pulmonology or cardiology coordination, right heart catheterization documentation, REMS enrollment (Adempas has REMS for teratogenicity), and ongoing renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Adempas PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your specialist for required documentation, follow up with the manufacturer’s program until approval, manage REMS pregnancy compliance, manage your refills, and handle annual re-certification.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Adempas enrollment — from the initial application through ongoing refills, REMS compliance, and re-enrollment — so you never face a gap in your pulmonary hypertension treatment.
Pharmacy Price Comparison
- Without assistance, Adempas costs tens of thousands of dollars per month at specialty pharmacies. Discount cards offer minimal relief at this price point, but a Patient Assistance Program can make this rare-disease therapy accessible if you qualify. The table below compares typical retail pricing:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic tadalafil/ambrisentan | ~$50/mo | Generic PAH alts |
| Walgreens | ~$19,500/mo | Save substantially |
| CVS Pharmacy | ~$20,000/mo | Save substantially |
| Walmart | ~$17,000/mo | Save substantially |
| Specialty pharmacy | ~$16,000/mo | Save substantially |
| Generic sildenafil (PAH alt) | ~$30/mo | Generic PDE5 alt (PAH only) |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Adempas — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Adempas Prescription Program?
The Adempas Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, REMS compliance, and ongoing management. Our $69.95 per month covers full advocacy so you focus on your health, not paperwork. Adempas is the only FDA-approved oral therapy for CTEPH — after pulmonary endarterectomy or in inoperable disease.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Adempas assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Adempas is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Adempas:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $16,000–$20,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Adempas assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Adempas Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Adempas:
Adempas is a first-in-class soluble guanylate cyclase (sGC) stimulator. Directly stimulates sGC (a different receptor than PDE5 inhibitors target) — increases cGMP production, causing pulmonary vascular smooth muscle relaxation. First and only FDA-approved oral therapy for CTEPH after surgery or in inoperable patients. Also approved for PAH. PATENT (PAH) and CHEST (CTEPH) trials established efficacy.
How It Works:
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) both involve elevated pulmonary vascular resistance leading to right heart strain and eventual failure. The nitric oxide signaling pathway through soluble guanylate cyclase to cGMP to vasodilation is impaired in pulmonary hypertension. Riociguat directly stimulates sGC (independent of NO) and also sensitizes sGC to endogenous NO — a dual mechanism increasing cGMP in the pulmonary vasculature, causing smooth muscle relaxation and vasodilation. Distinct from PDE5 inhibitors. PATENT-1/2 established PAH efficacy; CHEST-1/2 established CTEPH efficacy.
Form and Use:
Adempas 0.5, 1, 1.5, 2, 2.5 mg tablets. Starting dose 1 mg three times daily. Uptitrate by 0.5 mg every 2 weeks based on systolic BP and tolerability, up to 2.5 mg three times daily maximum. Take with or without food. REMS pregnancy program mandatory — pregnancy testing before and monthly during therapy in women of childbearing potential; effective contraception required. Monitor BP; hold or reduce for hypotension.
Generic Availability:
No generic Adempas. For PAH: PDE5 inhibitors (generic sildenafil/Revatio, generic tadalafil/Adcirca), endothelin receptor antagonists (generic ambrisentan/Letairis, generic bosentan/Tracleer, macitentan/Opsumit), prostacyclin pathway (epoprostenol/Flolan generic, treprostinil/Remodulin/Tyvaso/Orenitram, iloprost/Ventavis, selexipag/Uptravi), sotatercept (Winrevair — newer activin signaling inhibitor). For CTEPH: pulmonary endarterectomy is potentially curative surgery; balloon pulmonary angioplasty (BPA) for inoperable/residual disease; Adempas is the only FDA-approved oral therapy for CTEPH. Referral to pulmonary hypertension expert center essential.
Warnings:
Boxed warning: embryo-fetal toxicity — teratogenic in animal studies. REMS mandatory — pregnancy testing before, monthly during, and 1 month after therapy in women of childbearing potential; effective contraception required. Contraindicated: pregnancy, concomitant use with nitrates or NO donors (severe hypotension), concomitant use with PDE5 inhibitors (severe hypotension — do not combine), pulmonary hypertension associated with idiopathic interstitial pneumonias (increased mortality per RISE-IIP). Other: hypotension, bleeding (including pulmonary), pulmonary edema in PVOD patients (rare), GI effects, headache, dizziness. Strong CYP inhibitors increase levels; smoking reduces levels.
FAQ (Frequently Asked Questions)
How much does Adempas cost without insurance?
$16,000–$20,000 per month. Annual cost exceeds $200,000. Specialty pharmacy and Patient Assistance Programs are essential.
Why is Adempas the only FDA-approved oral therapy for CTEPH?
The CHEST trials demonstrated Adempas improved exercise capacity and hemodynamics in CTEPH patients who were inoperable or had persistent PH after pulmonary endarterectomy. No other oral therapies have this specific indication. Pulmonary endarterectomy is potentially curative surgery for operable CTEPH; BPA is a procedural option for inoperable disease.
Can I take Adempas with sildenafil or tadalafil?
No — contraindicated combination. Adempas and PDE5 inhibitors both work on the cGMP pathway; combining causes severe hypotension. Choose one or the other. This applies whether PDE5 inhibitors are used for PAH (Revatio, Adcirca) or erectile dysfunction (Viagra, Cialis).
Can I take Adempas with nitroglycerin or other nitrates?
No — contraindicated. Nitrates and Adempas both increase cGMP causing severe hypotension. This includes sublingual nitroglycerin, isosorbide, and other nitrates. Discuss all cardiovascular medications with your specialist before starting Adempas.
Why is pregnancy testing mandatory (REMS)?
Adempas is teratogenic in animal studies. The REMS program mandates pregnancy testing before therapy, monthly during therapy, and 1 month after discontinuation in women of childbearing potential. Effective contraception is required throughout therapy and for 1 month after the last dose.
Take Control of Your Medication Costs
Pulmonary hypertension therapy should not be derailed by cost — and CTEPH treatment options are unique with Adempas. Our Adempas advocacy team is ready to verify your eligibility, complete the manufacturer application, and manage your prescription — for a flat $69.95 per month. If we cannot help you access Adempas through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.